Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telavancin Observational Use Registry (TOUR)

NCT02288234 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.

NCT NCT02288234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02288234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telavancin Observational Use Registry (TOUR)
Lead sponsor
Cumberland Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
November 30, 2014
Completion date
October 31, 2017
Enrollment
1,063 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complicated skin and skin structure infections, gram positive infection, hospital acquired bacterial pneumonia, ventilator associated bacterial pneumonia